SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel ($INTC) is surging after a strong earnings report, with revenue and EPS exceeding expectations, sparking optimism about its turnaround. Community members are discussing the potential for a short squeeze and future growth, fueled by government investment and new strategic directions. Positive commentary surrounds CEO Lip Bu Tan, with many believing he is steering the company toward a comeback in the semiconductor industry.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending following news of its biometric system deployment at Chicago O'Hare International Airport. Community members are speculating about further airport expansions and potential TSA contracts, contributing to bullish sentiment. Discussions also involve the stock's potential for a short squeeze and comparisons to other AI stocks.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amidst discussions around meme coins and potential gains, with some community members drawing comparisons to previous rallies of similar assets like Dogecoin and Pepe. Conversations also include speculation about market cycles, potential 'scam' allegations, and whether SHIB can still deliver significant returns. The community is actively debating its future, especially in light of broader crypto market conditions.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is trending amid speculation and conflicting reports about potential government investment in quantum computing companies, driving high trading volume. Community discussions revolve around the accuracy of news reports and the potential impact of government involvement on the sector. Some traders believe QBTS could benefit significantly due to its position in the quantum optimization market.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express strong conviction and highlight its stability, particularly its consistent floor and liquidity depth, despite market volatility. The community frequently references WAGMI alongside other popular meme coins like DOGE, SHIB, and PEPE, suggesting it's viewed as a potential contender in the meme economy. Some community members are discussing the potential for substantial returns due to the strong community and consistent liquidity.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor is trending as the community analyzes recent quarterly earnings and future sales estimates, with some investors seeing a buying opportunity despite revised revenue outlooks. Community members are actively debating the impact of tariffs, consumer spending, and brand growth, especially for HOKA and UGG. Some traders are highlighting technical indicators and historical support levels to evaluate potential price movements.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is trending amid volatile market conditions, with community members actively discussing dip-buying strategies and potential recovery points. The conversation includes comparisons to other meme coins like SHIB and DOGE, while some traders are exploring new, low market cap opportunities within the memecoin space. Despite recent price drops, some remain optimistic about a potential rebound and long-term growth.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is trending as investors digest recent earnings and a drop in gold production, despite beating expectations. The community is discussing the CEO's performance on the earnings call and debating whether the stock's reaction is an overreaction, considering the surge in gold prices. Some traders are weighing the potential for share buybacks and dividend increases, while others consider switching to physical gold.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending as investors discuss its potential in the drone and defense sectors, focusing on the company's partnerships and future growth. Community members are weighing in on the recent stock dilution vote and its implications for the company's expansion plans and defense contracts. Bullish sentiment revolves around long-term growth prospects and potential government contracts.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as investors discuss its potential following Intel's strong earnings, highlighting the increasing demand for AI compute. Community members are weighing in on the recent pullback, with some seeing it as a buying opportunity, while others remain cautious about the broader market volatility. Positive sentiment is fueled by the company's AI cloud infrastructure and partnerships, including its autonomous vehicle subsidiary Avride.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why

COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Stifel said the plunge in Compass Pathways shares was “significantly overdone” after data showed that the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/compass-pathways-stock-slumps-after-positive-late-stage-trial-results-from-psychedelic-drug-underwhelm-analysts/chm59LwRRdc">company’s COMP360</a> met the primary endpoint in a Phase 3 trial for treatment-resistant depression.Compass Pathways shares plunged 49.2% to close at $2.35 on Monday before recovering 7.2% to $2.52 in after-hours trading.While the 3.6-point difference on the Montgomery-Åsberg depression rating scale (MADRS) was “a little lighter than expected,” the firm noted the results were “clearly positive” from a regulatory perspective.Stifel added that the effect size was “pretty good” for a treatment-resistant population and argued that in neuropsychiatry, commercial success is not always determined by effect size alone.&nbsp;The firm maintained a ‘Buy’ rating on the stock and a $11 price target.On Monday, Compass said that a single 25 mg dose of COMP360 meaningfully and statistically significantly reduced depression symptoms vs. placebo at week 6.The p-value was less than 0.001, meaning there was less than a 0.1% chance the result was due to chance.Compass Pathways is also conducting a second Phase 3 study evaluating the effects of two doses of COMP360 given three weeks apart.&nbsp;A second late-stage study, COMP006, is ongoing and will assess the effect of two fixed doses, which will be given three weeks apart.&nbsp;The company plans to discuss the results with the U.S. Food and Drug Administration.Following the trial update, Evercore ISI downgraded Compass to 'In Line' from 'Outperform' and cut its price target to $6 from $11, calling the 3.6-point symptom reduction "underwhelming" and citing questions around the drug's long-term durability.Meanwhile, H.C. Wainwright maintained a 'Buy' rating and $45 target, calling the results "a historic first for psychedelic therapy" and viewing COMP360 as a potential first-in-class option in a large, underserved market.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 7,567% surge in 24-hour message volume.One user said they were still holding Compass Pathways shares despite disappointment over the more than 50% drop following positive trial results, noting that the after-hours price action provided some relief.<stembedurl>https://stocktwits.com/WMWilson/message/618751654</stembedurl>Another user pointed out that a similarly weak initial reaction had occurred with Sagimet Biosciences after its Phase 3 data, but the stock recovered.<stembedurl>https://stocktwits.com/LoonaManStan/message/618762972</stembedurl>The stock has declined 43.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stifel Says Compass Pathways Selloff 'Significantly Overdone' After Psilocybin Trial Data

The company is also conducting a second Phase 3 study evaluating the effects of two doses of COMP360 given three weeks apart. 

Equity

Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx">results</a> from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.COMP360 is a synthetic, proprietary formulation of psilocybin. Psilocybin is part of a group of drugs called psychedelics or hallucinogens with the ability to alter one’s sense of perception.Compass Pathways said that a single dose of the drug reduced symptom severity by 3.6 points from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) as compared to placebo at week 6.The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.The company is also running another late-stage trial for the drug, which aims to evaluate the efficacy of two fixed doses taken three weeks apart.According to Compass Pathways, an estimated 21 million adults in the U.S. suffer from major depression, and approximately 9 million are drug-treated.Approximately a third of patients with major depressive disorder will develop treatment-resistant depression, which is defined as an inadequate response to two or more appropriate courses of approved medications.Following the announcement, Evercore ISI downgraded Compass Pathways to ‘In Line’ from ‘Outperform’ with a price target of $6, down from $11.The reduction in symptom severity by 3.6 points as compared to placebo on a standardized depression scale "underwhelmed," the analyst told investors, as per TheFly.This dataset does indicate Compass may have an approvable drug, but the firm noted that durability is a key component for commercial success, and this will remain a question with relatively unclear durability in a mid-stage trial and a weaker effect at 6 weeks in the late-stage trial.H.C. Wainright, however, is more optimistic and noted that the results from the late-stage study mark "a historic first for a psychedelic therapy." The data also positions COMP360 as "a potential first-in-class treatment in a large, underserved depression market," said the analyst, who reiterated a ‘Buy’ rating and $45 price target on the shares.On Stocktwits, retail sentiment around CMPS jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:631/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_23_at_12_27_47_PM_png_d7e1356560.webp" alt="CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits" width="631" height="60"><figcaption>CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that while the late-stage results were good, the market wants ‘groundbreaking’ results.<stembedurl>https://stocktwits.com/aaronmag13/message/618680560</stembedurl><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is down by about 35% this year and nearly 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/rezolve-ai-to-be-added-to-russell-indices-after-revenue-surge/chm57C7RRdR">Rezolve Ai To Be Added To Russell Indices After Revenue Surge: Retail Echoes Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Exxon Mobil, Chevron rise premarket; Compass Pathways dips

Investing.com - U.S. stock index futures were hovering around the flatline on Monday, as investors took some caution as they gauged the fallout from weekend U.S. strikes on Iranian nuclear facilities.

COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know

Shares of Mind Medicine Inc. climbed 3.6% on Thursday and extended gains after hours, with retail sentiment improving following the company's fourth-quarter earnings report.The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier, largely due to higher research and development costs tied to its MM120 and MM402 programs.&nbsp;MM120, MindMed's lead drug candidate, is designed to treat generalized anxiety disorder (GAD), while MM402 is being developed to address core symptoms of Autism Spectrum Disorder (ASD).However, the company's adjusted Q4 loss per share of $0.41 narrowed from $0.59 a year ago, though it missed analyst expectations of a $0.28 loss.CEO Rob Barrow remained upbeat, stating that 2024 was a "year of significant progress" and that the company had achieved key milestones leading into multiple Phase 3 clinical readouts for MM120, which he expects to drive MindMed's next growth phase.On Stocktwits, sentiment for MNMD shifted from 'bearish' to 'neutral' in the 24 hours leading up to Thursday, with message volume surging 250%.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MNMD_sentiment_and_message_volume_as_of_March_6_8b8a5ebcbf.png" alt="MNMD sentiment and message volume as of March 6.png" width="1316" height="302"><figcaption>MNMD sentiment and message volume as of March 6 | source: Stocktwits</figcaption></figure>One user expressed confidence in MM120's potential, saying, "Once Phase 3 [of the MM120 study] passes, this is going to blow up."<stembedurl>https://stocktwits.com/Bball4/message/606995440</stembedurl>Another key factor boosting optimism was MindMed's strong cash reserves. The company ended 2024 with $273.7 million in cash and cash equivalents, up from $99.7 million a year earlier, which the company expects to be sufficient to support operations into 2027.One user wrote, "We won't have to do any more reverse splits. MNMD has cash reserves until approvals."<stembedurl>https://stocktwits.com/BullsVSBearsVSYoMomma/message/607108323</stembedurl>Additionally, traders pointed to potential government&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mnmd-stock-soars-after-rfk-jr-confirmed-as-hhs-chief/ch5iJvpRH6">support</a> under new Health and Human Services chief Robert F. Kennedy Jr., who has previously advocated for the decriminalization of psychedelics for therapeutic use.The company also plans regulatory and pre-commercialization activities for MM120's orally disintegrating tablet (ODT) version.One watcher pointed out that although MNMD lags behind competitor Compass Pathways in clinical progress, its broader drug pipeline gives it an edge.Mind Medicine shares remain down over 7% year-to-date but have gained over 10% in the past 12 months.&nbsp;According to Koyfin, of the 11 analysts covering the stock, seven rate it a 'buy,' while four have a 'strong buy' rating.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish

The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at...

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial...

Shares of Mind Medicine Inc. (MNMD) surged more than 15% Friday afternoon, on track for their best session since April 2024, as retail traders cheered Robert F. Kennedy Jr.’s confirmation as U.S. Health and Human Services secretary.The stock is now set to post weekly gains of over 22%, its strongest performance since the week of Donald Trump’s 2024 election victory in November.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MNMD_sentiment_Feb_14_dada4484f8.png" alt="MNMD sentiment Feb 14.png" width="1318" height="324"><figcaption>MNMD sentiment Feb 14 as of 2:30 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment turned even more bullish, with message volume skyrocketing 720% in the past three months amid RFK Jr.’s rise to the cabinet.“The RFK bump,” one user wrote, echoing several other posts, while another predicted a “big breakout” next week.&nbsp;<stembedurl>https://stocktwits.com/mpferd/message/604362153</stembedurl><stembedurl>https://stocktwits.com/Knot2/message/604306853</stembedurl>Kennedy has previously&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/livecoverage/trump-cabinet-confirmation-hearings/card/what-has-rfk-jr-said-about-weight-loss-drugs-antidepressants-and-psychedelics--eAaDAxA6vQaSVMeBPlEs">advocated</a> for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.Wall Street has also taken notice.&nbsp;Earlier this month, Chardan named Mind Medicine as a top biotech pick for 2025, citing strong Phase 2 results for its lead drug candidate MM120, which targets generalized anxiety disorder (GAD).&nbsp;The research firm has a ‘Buy’ rating with a $20 price target — implying a doubling from current levels — and projects potential MM120 peak sales of over $1 billion by 2026.In January, Evercore ISI <a href="https://stocktwits.com/news-articles/markets/equity/mnmd-stock-rises-on-evercore-isi-rating/chbVQU4RYM">initiated</a> coverage with an ‘Outperform’ rating and a $23 target, highlighting Mind Medicine’s innovative oral LSD formulation and its potential in treating both GAD and major depressive disorder (MDD).Still, not everyone’s betting on more gains. Short interest has climbed from 12.9% at the start of the year to 14.2% by January’s end, per Koyfin data.<a href="https://stocktwits.com/symbol/MNMD">Mind Medicine shares</a> have gained over 42% year-to-date, outperforming Compass Pathways but lagging Atai Life Sciences’ 79% surge. Those two companies are also developing psychedelic therapeutics.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Robert F. Kennedy Jr. speaks after being sworn in as Secretary of Health and Human Services in the Oval Office at the White House on February 13, 2025 in Washington, DC. (Photo by Andrew Harnik/Getty Images)

Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months

Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.

Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

CMPS
COMPASS Pathways

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CMPS News

CMPSCOMPASS Pathways